SQUARE

e-

SQUARE

 
Healthcare online Keeping you up-to-date
VOL.  15     ISSUE:  5   May 2017 Medical Services Department

SQUARE Pharmaceuticals Ltd.

Features

EDITORIAL TEAM

OMAR AKRAMUR RAB

MBBS, FCGP, FIAGP,

P G Dip. Business Management

MAHFUZUR RAHMAN

MBBS, MBA

MD. SAIFUL ALAM

MBBS, MPH

 

EDITORIAL

Hope that you are enjoying this online healthcare bulletin.

Our current issue focused on some interesting features like -

"Colon Cancer Risk !", "Infertility !", "Chocolate & Irregular Heartbeat !", "Diabetes Drug Alert !",  "Water & Fat !", "Antibiotic Alert !".

In our regular feature, we have some new products information of SQUARE Pharmaceuticals Ltd. as well.

We will appreciate your feedback !

Click on to reply mode.

Yours sincerely,

 

Editorial Team

Reply Mode      : e-square@squaregroup.com

The views expressed in this publication do not necessarily reflect those of its editor or SQUARE Pharmaceuticals Ltd.

 Colon Cancer Risk !

Blacks More Prone to Colon Cancers That Arise Between Colonoscopies: Study

Colon cancer guidelines now recommend a colonoscopy every 10 years, beginning at age 50 for people at average risk for the disease. But a new study finds that older black Americans are far more likely than whites to develop a colon cancer in the decade-long gap between these screenings. Some of this may be due to where black patients receive their colonoscopy, the lead researcher added. Blacks and other minorities more frequently received colonoscopies from physicians with lower polyp detection rates, suggesting there was lower quality of care, quoted by lead researcher. Interval colorectal cancer occurs when the disease develops after a screening colonoscopy that finds no sign of cancer, but before the patient's next screening. According to the researchers, interval colon cancer accounts for up to 8 percent of all cases. In the new study, black patients had a 31 percent higher risk for interval colon cancer than white patients. The lead researcher also found that the risk was significantly higher for colon cancers occurring in the distal colon, compared to the proximal portion of the tract. Finally, the top researcher said, black patients were more likely than whites to have colonoscopies performed by physicians who had lower polyp detection rates, a measure of physician quality. However, this difference in physicians did not fully explain the racial discrepancy in risk. Further research in this area is needed given the high rate of colon cancer among blacks, who have the highest incidence and death rates from the disease of any race/ethnic group in the United States, the lead researcher added.

SOURCE: HealthDay News, May 2017

Return to top

 Infertility !

 Century-Old Technique May Help Infertile Couples Conceive Without IVF

A 100-year-old medical treatment could help infertile women get pregnant without undergoing pricey in vitro fertilization (IVF), a new study suggests. The method was first used in 1917 and involves flushing a woman's fallopian tubes with iodized poppy seed oil. Over the past century, pregnancy rates among infertile women reportedly increased after their tubes had been flushed with either water or oil during, a dye test of the fallopian tubes under X-ray, explained by lead researcher. Until now, it has been unclear whether the type of solution used in the procedure was influencing the change in fertility or not. Our results have been even more exciting than we could have predicted, helping to confirm that an age-old medical technique still has an important place in modern medicine, the lead researcher added. This study included more than 1,100 women being treated for infertility who had their fallopian tubes flushed with either the poppy seed oil or water. Successful pregnancies occurred within six months for nearly 40 percent of the women in the oil group and 29 percent of those in the water group, the researchers reported May 18 in the New England Journal of Medicine. The poppy seed oil used in the study is available in 47 countries worldwide, the lead researcher noted. The rates of successful pregnancy were significantly higher in the oil-based group, and after only one treatment. This is an important outcome for women who would have had no other course of action other than to seek IVF treatment. It offers new hope to infertile couples. 

SOURCE: HealthDay News, May 2017

Return to top

 
 
 Chocolate & Irregular Heartbeat !

Could Chocolate Guard Against an Irregular Heartbeat?

New research suggests the sweet might help keep a common and dangerous form of an irregular heartbeat at bay. The study of more than 55,000 people in Denmark found that those who favored chocolate tended to have a lower risk of atrial fibrillation, an irregular heartbeat that raises stroke risk. The study tracked people's health for more than 13 years, over which time more than 3,300 cases of atrial fibrillation emerged. The study wasn't designed to prove cause and effect. However, compared with people who ate one ounce serving of chocolate less than once a month, the risk of atrial fibrillation was 10 percent lower among those who ate one to three servings a month, 17 percent lower among those who ate one serving a week, and 20 percent lower among those who ate two to six servings of chocolate a week. But the benefit then leveled off, with a 16 percent lower risk of atrial fibrillation among adults who ate one or more one ounce servings of chocolate a day. However, lead researcher addressed that cardiovascular health relies on more than just chocolate intake. Factors such as regular aerobic exercise and other healthy behaviors could be a benefit as well. According to the study authors, prior research has suggested that cocoa and cocoa-containing foods can benefit the heart. That's because they contain high levels of flavanols, which may improve blood vessel function.

SOURCE: HealthDay News, May 2017

Return to top

 
 
 Diabetes Drug Alert !

                                         Diabetes Drug Gets FDA Warning Due to Amputation Risk

The type 2 diabetes prescription drug canagliflozin appears to increase the risk of leg and foot amputations, the U.S. Food and Drug Administration says. The FDA is requiring the medications to carry new warnings about the risk. The required warnings on the drug's labeling include the most serious and prominent boxed warning. The agency's decision is based on data from two large clinical trials showing that leg and foot amputations occurred about twice as often in patients taking canagliflozin as among those taking a placebo. Amputations of the toe and middle of the foot were the most common, but leg amputations below and above the knee also occurred. Some patients had more than one amputation; some had amputations involving both limbs, according to the FDA. Left untreated, high blood sugar levels can cause a number of possible complications, including heart disease, kidney problems and amputations, according to the American Diabetes Association. Canagliflozin is meant to be used with diet and exercise to lower blood sugar in adults with type 2 diabetes. It belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors. These drugs lower blood sugar levels by causing the kidneys to remove sugar from the body through the urine. Patients taking canagliflozin should immediately notify their health care providers if they develop new pain or tenderness, sores or ulcers, or infections in the legs or feet, the FDA said in a news release. Patients should not stop taking their medication without first talking to their health care provider. Before prescribing canagliflozin to patients, doctors should consider factors that may predispose patients to the need for amputations, including a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers, the FDA said. In addition, doctors should monitor patients taking canagliflozin for the above signs and symptoms, and discontinue canagliflozin if these complications occur.

SOURCE: HealthDay News, May 2017

Return to top

 
 
 Water & Fat !

                                                                Drink Water, Fight Fat?

If you choose a glass of water instead of a beer or a sugar-sweetened soda at least once a day, you can reduce your risk of obesity, a new study claims. Researchers followed almost 16,000 adults in Spain for an average of 8.5 years. None were obese at the start of the study. During that study, almost 900 participants became obese. The study found that drinking a glass of water instead of a beer every day reduced the risk of obesity by 20 percent. Switching one sugar-sweetened soft drink for water every day was associated with a 15 percent lower risk of developing obesity. Those who substituted water for beer also had a slight decrease in average weight of 0.7 pounds over four years. The study cannot prove a direct cause-and-effect link, but the researchers did try to account for other factors that might affect risk, such as age, family history of obesity and physical activity levels. The lead researcher also found that replacing other types of beverages with water didn't reduce obesity risk. The other beverages included: whole milk, reduced-fat milk, skim milk, wine, spirits, diet sodas, coffee, orange juice, and other juices. Further studies based on real interventions are needed to confirm these potential effects. As obesity carries a high risk for the development of other diseases like diabetes or cardiovascular disease, the possible effects of substituting these beverages with water is an important target to consider in future public health research, the lead researcher added.

SOURCE: HealthDay News, May 2017

Return to top

 
 
 Antibiotic Alert !

                                                       First-Try Antibiotics Now Fail in 1 in 4 Adult Pneumonia Cases

The first prescription of an antibiotic that the average U.S. adult with pneumonia receives is now ineffective in about a quarter of cases. In these cases, more or different antibiotics were needed, or the patient's condition worsened to require ER admission or hospitalization within a month of the antibiotics being taken, the lead researcher said. The results are concerning, because pneumonia is the leading cause of death from infectious disease in the United States, lead researcher added. The additional antibiotic therapy noted in the study increases the risk of antibiotic resistance and complications like C. difficile infection, which is difficult to treat and may be life-threatening, especially for older adults. Infectious disease experts have sounded the alarm for years on the growing problem of antibiotic resistance. One expert who reviewed the new findings said they highlight that threat. The fact that a quarter of pneumonia patients failed their initial antibiotic therapy could be related to change in the bacterial resistance in the community. Lead researcher tracked data from nearly 252,000 adults who were prescribed antibiotics to treat pneumonia contracted outside of a hospital. Patients were cared for at either a doctor's office or other outpatient facility. Just over 22 percent of the patients did not respond to their initial prescription of antibiotic treatment, the lead researcher added. Any update should include data on what risk factors leave patients vulnerable to antibiotic failure, top researcher added. Patients over the age of 65 were nearly twice as likely to be hospitalized compared to younger patients and elderly patients are more vulnerable and should be treated more carefully, potentially with more aggressive to antibiotic therapy.

SOURCE: HealthDay News, May 2017

Return to top

 
 

New Products of SQUARE Pharmaceuticals Ltd.

  Product SuxalaxTM IM/IV Injection
  Generic Name Suxamethonium Chloride BP
  Strength

2 ml Injection

Dosage form IM/IV
  Therapeutic Category Muscle Relaxant
Product Flindof TM 200 Tablet         
Generic Name

Doxofylline INN

Strength 200 mg
Dosage form Tablet
Therapeutic Category Oral Bronchodilator
  Product Flindof TM 400 Tablet
Generic Name Doxofylline INN
  Strength 400 mg
Dosage form Tablet
  Therapeutic Category Oral Bronchodilator

Return to top

 

Copyright 2017 SQUARE Pharmaceuticals Ltd. All rights reserved.